Wednesday, July 8, 2026

Patent intelligence · US

US 7198783

Sensitization of neoplastic cells to radiation therapy with reovirus

granted A61KA61K35/765A61K41/0038A61P
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 1
Applicant portfolio 66
Patent details — US 7198783
Jurisdiction
US
Status
granted
Grant date
Apr 3, 2007
Expiration
Mar 29, 2027
Claims
25
CPC classes
A61K, A61K35/765, A61K41/0038, A61P
View on Google Patents ↗

Quick answer

US 7198783 (Sensitization of neoplastic cells to radiation therapy with reovirus) is held by ONCOLYTICS BIOTECH INC.. Status: granted. Granted Apr 3, 2007. Expires Mar 29, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
25
CPC classes
A61K, A61K35/765, A61K41/0038, A61P, A61P35/00, A61P35/02

More from ONCOLYTICS BIOTECH INC.

Related pharmaceutical patents in our USPTO index.

  1. US 11542526

    Oncolytic adenoviral vector and methods of use

    Unleash Immuno Oncolytics, Inc. · Expires Dec 29, 2042

    granted
  2. US 11246930

    Reoviruses having modified sequences

    ONCOLYTICS BIOTECH INC. · Expires Feb 10, 2042

    granted
  3. US 10596260

    Reoviruses having modified sequences

    ONCOLYTICS BIOTECH INC. · Expires Mar 19, 2040

    granted
  4. US 10167452

    Viral purification methods

    ONCOLYTICS BIOTECH INC. · Expires Dec 27, 2038

    granted
  5. US 10039827

    Reoviruses having modified sequences

    ONCOLYTICS BIOTECH INC. · Expires Aug 2, 2038

    granted
  6. US 9610352

    Lyophilized viral formulations

    ONCOLYTICS BIOTECH INC. · Expires Mar 30, 2037

    granted
  7. US 9610309

    Liquid viral formulations

    ONCOLYTICS BIOTECH INC. · Expires Mar 30, 2037

    granted
  8. US 9365823

    Virus clearance of neoplastic cells from mixed cellular compositions

    ONCOLYTICS BIOTECH INC. · Expires Jun 9, 2036

    granted

Frequently asked questions

What is US patent 7198783?

US 7198783 (Sensitization of neoplastic cells to radiation therapy with reovirus) is held by ONCOLYTICS BIOTECH INC.. Status: granted. Granted Apr 3, 2007. Expires Mar 29, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7198783?

ONCOLYTICS BIOTECH INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 66 pharmaceutical patents for this assignee.

When does US 7198783 expire?

Our index shows an expiration date of Mar 29, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.